Celularity Inc. Current Income Tax Expense (Benefit)
Celularity Inc. (CELU) reported Current Income Tax Expense (Benefit) of $10.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-05-08.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2025-05-08
- Celularity Inc. current income tax expense (benefit) for fiscal 2023 was $10.00K, a 23.08% decline from fiscal 2022.
- Celularity Inc. current income tax expense (benefit) for fiscal 2022 was $13.00K, a 23.53% decline from fiscal 2021.
- Celularity Inc. current income tax expense (benefit) for fiscal 2021 was $17.00K, a 0.00% change from fiscal 2020.
- Celularity Inc. current income tax expense (benefit) for fiscal 2020 was $17.00K, a 97.46% decline from fiscal 2019.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2023-12-31 | $10.00K 10-K · filed 2025-05-08 | |
| 2022-12-31 | $13.00K 10-K · filed 2024-07-30 | |
| 2021-12-31 | $17.00K 10-K · filed 2023-03-31 | |
| 2020-12-31 | $17.00K 10-K · filed 2022-03-31 | $189.39K 10-K · filed 2021-03-04 |
| 2019-12-31 | $669.88K 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |